Praxis Precision Medicines, Inc.
NASDAQ: PRAX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Marcio Silva De'Souza
- Employees
- 116
- Headquarters
- Boston, United States
- IPO year
- 2020
- Market cap
- $6.0B
- Website
- https://www.praxismedicines.com
Loading PRAX…
Loading profile data…Frequently asked questions about PRAX
What does Praxis Precision Medicines, Inc. (PRAX) do?
Praxis Precision Medicines, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating innovative treatments for central nervous system (CNS) conditions that stem from an imbalance in neuronal activity. The company's primary investigational compounds currently undergoing evaluation include: PRAX-114, an extrasynaptic...
Where does PRAX trade?
Praxis Precision Medicines, Inc. (PRAX) trades on the NASDAQ Global Select.
What sector is PRAX in?
Praxis Precision Medicines, Inc. (PRAX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Praxis Precision Medicines, Inc.?
Marcio Silva De'Souza is the chief executive officer of Praxis Precision Medicines, Inc. (PRAX).
Where is Praxis Precision Medicines, Inc. headquartered?
Praxis Precision Medicines, Inc. is headquartered in United States.
Does PRAX pay a dividend?
Praxis Precision Medicines, Inc. (PRAX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did PRAX go public?
Praxis Precision Medicines, Inc. (PRAX) completed its initial public offering in 2020.